BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis
Bayer (United States) · Biohaven Pharmaceuticals (United States)
Abstract
The RAS/RAF signaling pathway is an important mediator of tumor cell proliferation and angiogenesis. The novel bi-aryl urea BAY 43-9006 is a potent inhibitor of Raf-1, a member of the RAF/MEK/ERK signaling pathway. Additional characterization showed that BAY 43-9006 suppresses both wild-type and V599E mutant BRAF activity in vitro. In addition, BAY 43-9006 demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular endothelial growth factor receptor (VEGFR)-2, VEGFR-3, platelet-derived growth factor receptor beta, Flt-3, and c-KIT. In cellular mechanistic assays, BAY 43-9006 demonstrated inhibition of the mitogen-activated…
Citation impact
- FWCI
- 51.95
- Percentile
- 100%
- References
- 36
Authors
26- SMScott M. WilhelmCorresponding
Bayer (United States), Biohaven Pharmaceuticals (United States)
- CCChristopher Carter
Bayer (United States), Biohaven Pharmaceuticals (United States)
- LTLiYa Tang
Bayer (United States), Biohaven Pharmaceuticals (United States)
- DWDean Wilkie
Bayer (United States), Biohaven Pharmaceuticals (United States)
- AMAngela McNabola
Bayer (United States), Biohaven Pharmaceuticals (United States)
Topics & keywords
- Cancer research
- Receptor tyrosine kinase
- MAPK/ERK pathway
- MEK inhibitor
- KRAS
- Angiogenesis
- Growth factor receptor
- Signal transduction
- Good health and well-being